Table 3.
Chemotherapy Administration for HIV-Associated Non-CNS Lymphoma
| DLBCL (n=15) | BL (n=9) | HL (n=15) | |
|---|---|---|---|
| Cycles planned | |||
| Total | 82 | 55 | 80 |
| Per patient | 5.5 | 6.1 | 5.3 |
| Cycles completed | |||
| Total | 75 | 50 | 63 |
| Per patient | 5.0 | 5.6 | 4.2 |
| % completed | 91% | 91% | 79% |
| Rituximab | |||
| % of cycles | 52% | 56% | — |
| % of patients | 59% | 56% | — |
| Dose reduction | |||
| % of cycles | 31% | 2% | 27% |
| Interruption | |||
| % of cycles | 1% | 5% | 10% |
| Delay | |||
| % of cycles | 19% | 33% | 22% |
| Dose reduction, interruption, or delay | |||
| % of cycles | 43% | 36% | 49% |
| Dose reduction, interruption, or delay in >25% of cycles | |||
| % of patients | 69% | 75% | 57% |
| Completed stage-appropriate therapy | |||
| % of patients | 73% | 44% | 67% |
DLBCL, diffuse large B cell lymphoma; BL, Burkitt lymphoma; HL, Hodgkin lymphoma.